|
|
|
Volumn 4, Issue 6, 2005, Pages 718-724
|
|
Safety and efficacy of alefacept in elderly patients and other special populations.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEFACEPT;
DERMATOLOGICAL AGENT;
HYBRID PROTEIN;
AGE;
AGED;
ARTICLE;
CHOLELITHIASIS;
CHRONIC DISEASE;
CLINICAL TRIAL;
COMORBIDITY;
CONTROLLED CLINICAL TRIAL;
DIABETES MELLITUS;
DRUG ADMINISTRATION;
HOSPITALIZATION;
HUMAN;
INTRAMUSCULAR DRUG ADMINISTRATION;
INTRAVENOUS DRUG ADMINISTRATION;
MULTICENTER STUDY;
OBESITY;
PSORIASIS;
RANDOMIZED CONTROLLED TRIAL;
TIME;
TREATMENT OUTCOME;
AGE FACTORS;
AGED;
CHOLELITHIASIS;
CHRONIC DISEASE;
COMORBIDITY;
DERMATOLOGIC AGENTS;
DIABETES MELLITUS;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
INJECTIONS, INTRAMUSCULAR;
INJECTIONS, INTRAVENOUS;
MULTICENTER STUDIES;
OBESITY;
PSORIASIS;
RANDOMIZED CONTROLLED TRIALS;
RECOMBINANT FUSION PROTEINS;
SEVERITY OF ILLNESS INDEX;
TIME FACTORS;
TREATMENT OUTCOME;
|
|
EID: 33644676553
PISSN: 15459616
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (23)
|
|
References (0)
|
